From SNPedia
| Geno
|
Mag
|
Summary
|
| (-;-)
|
3
|
CYP2D6*6 poor metabolizer phenotype
|
| (-;T)
|
2.1
|
possible CYP2D6 poor metabolizer phenotype
|
| (T;T)
|
0
|
normal
|
The (-) form of this SNP, representing a deletion of one nucleotide, causes a frameshift such that the resulting
CYP2D6 protein is nonfunctional. The associated allele is also known as CYP2D6*6, and there are several subtypes but they are all nonfunctional.
If two copies of this (or similar) changes are inherited, CYP2D6 poor metabolism ('PM') is observed.
CYP2D6 poor metabolism may affect the efficacy or degree of side effects of drugs metabolized by CYP2D6, such as dextromorphan, sparteine, nortriptyline, venlafaxine and codeine.
| PharmGKB | PA162316613 |
| Name | CYP2D6:1707 del T, CYP2D6*6 |
| Annotation | This variant is the defining SNP for CYP2D6*6 and encodes a non-functional variant of CYP2D6. Individuals with CYP2D6 *6/*4 , *5/*4 or *6/*6 genotypes are poor metabolizers of venlafaxine and are more prone to drug-induced side effects such as nausea, vomiting and diarrhea. However, CYP2D6 genotype does not seem to influence venlafaxine efficacy. |
| Gene | CYP2D6 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:16958828 |
| Drugs | venlafaxine |
| Diseases | Depression, Depressive Disorder, Depressive Disorder, Major, Diarrhea, Drug Toxicity, Nausea, Vomiting |
| Curation Level | Curated |
